注射用醋酸曲普瑞林联合孕三烯酮对子宫腺肌症患者Janus激酶2和信号转导及转录活化因子3表达的影响  

Effect of triptorelin acetate for injection combined with gestrinone on the expression of Janus kinase 2 and signal transduction and transcriptional activation factor 3 in patients with uterine adenomyosis

作　　者：王芳 王培珍 毛冬梅 WANG Fang;WANG Peizhen;MAO Dongmei(Department of Gynecology,Ganyu District People's Hospital of Lianyungang City,Lianyungang,Jiangsu,222100,China)

机构地区：[1]连云港市赣榆区人民医院妇科,江苏连云港222100

出　　处：《当代医学》2024年第24期49-53,共5页Contemporary Medicine

摘　　要：目的探究醋酸曲普瑞林注射液与孕三烯酮联用对子宫腺肌症的治疗效果,并分析其对Janus激酶2(Janus kinase 2,JAK2)及信号转导与转录活化因子3(signal transduction and transcriptional activation factor 3,STAT3)表达水平的影响。方法选取2022年1月至2023年1月连云港市赣榆区人民医院收治的60例子宫腺肌症患者为研究对象,随机分为对照组与联合组,每组30例。对照组行孕三烯酮治疗,联合组在对照组基础上加用注射用醋酸曲普瑞林治疗。比较两组一般指标[子宫内腹厚度、视觉模拟评分法(visual analog scale,VAS)评分、月经失血图(pictorial blood loss assessment chart,PBAC)评分、子宫体积]、性激素[卵泡生成激素(follicle-stimulating hormone,FSH)、雌二醇(estradiol,E_(2))、黄体生成激素(luteinising hormone,LH)]、肿瘤标志物[人附睾蛋白4(human epididymis protein,HE4)、糖类抗原125(carbohydrate antigen 125,CA125)、糖类抗原19-9(carbohydrate antigen 19-9,CA19-9)]、JAK2、STAT3、临床疗效及不良反应发生情况。结果治疗后,两组子宫内腹厚度均薄于治疗前,VAS、PBAC评分均低于治疗前,子宫体积均小于治疗前,且联合组子宫内腹厚度薄于对照组,VAS、PBAC评分均低于对照组,子宫体积小于对照组,差异有统计学意义(P<0.05)。治疗后,两组FSH、E_(2)、LH水平均低于治疗前,且联合组低于对照组,差异有统计学意义(P<0.05)。治疗后,两组CA125、CA19-9、HE4水平均低于治疗前,且联合组低于对照组,差异有统计学意义(P<0.05)。治疗后,两组JAK2、STAT3表达水平均低于治疗前,且联合组低于对照组,差异有统计学意义(P<0.05)。联合组治疗总有效率高于对照组,差异有统计学意义(P<0.05)。两组不良反应发生率比较差异无统计学意义。结论注射用醋酸曲普瑞林联合孕三烯酮治疗子宫腺肌症疗效显著,可降低患者性激素、HE4、CA125、CA19-9、JAK2、STAT3水平,促进临床恢复,且未增Objective To explore the effect of triptorelin acetate for injection combined with gestrinone on the expression of Janus kinase 2(JAK2)and signal transduction and transcriptional activation factor 3(STAT3)in patients with uterine adenomyosis.Methods 60 cases of uterine adenomyosis treated at Ganyu District People's Hospital of Lianyungang City from January 2022 to January 2023 were selected as the research subjects,and they were randomized into the control group and the combined group,with 30 cases in each group.The control group is treated with gestarenon and the combined group is treated with triprolinaceat injection on a control basis.The general indicators(intrauterine abdominal thickness,visual analog scale[VAS]score,pictorial blood loss assessment chart[PBAC]score,uterine volume),reproductive hormones(follicle-stimulating hormone[FSH],estradiol[E_(2)],luteinising hormone[LH]),tumor markers(human epididymis protein 4[HE4],carbohydrate antigen 125[CA125],carbohydrate antigen 19-9[CA19-9]),JAK2,STAT3,clinical efficacy and occurrence of adverse reactions were compared between the two groups.Results After treatment,the uterine abdominal thickness of the two groups were thinner than that before treatment,the VAS and PBAC scores were lower than those before treatment,the uterine volume were smaller than that before treatment,and the uterine abdominal thickness in the combined group was thinner than that in the control group,the VAS and PBAC scores were lower than those in the control group,and the uterine volume was smaller than that in the control group,the differences were statistically significant(P<0.05).After treatment,the levels of FSH,E_(2) and LH of the two groups were lower than those before treatment,and the combined group was lower than the control group,the differences were statistically significant(P<0.05).After treatment,the levels of CA125,CA19-9 and HE4 of the two groups were lower than those before treatment,and the combined group was lower than the control group,the differences were statistically

关 键 词：子宫腺肌症 注射用醋酸曲普瑞林 孕三烯酮 

分 类 号：R73[医药卫生—肿瘤]